Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 56.89% | 31.89% | -23.74% | -23.71% | 45.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.89% | 31.89% | -23.74% | -23.71% | 45.30% |
| Cost of Revenue | -1.20% | 19.16% | 9.78% | 12.63% | -1.81% |
| Gross Profit | 74.89% | 39.07% | -41.59% | -38.29% | 70.86% |
| SG&A Expenses | -15.99% | 16.84% | -0.95% | -2.47% | 55.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.64% | 16.93% | -0.64% | -2.05% | 53.22% |
| Operating Income | 23.64% | -15.24% | -1.49% | -0.29% | -54.14% |
| Income Before Tax | 22.07% | 62.24% | -1.52% | 5.96% | 25.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.07% | 62.24% | -1.52% | -2.06% | 25.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.07% | 62.24% | -1.52% | -2.06% | 25.35% |
| EBIT | 23.64% | -15.24% | -1.49% | -0.29% | -54.14% |
| EBITDA | 21.28% | -21.82% | -4.42% | -1.23% | -61.12% |
| EPS Basic | 24.24% | 66.09% | 15.79% | 14.86% | 37.71% |
| Normalized Basic EPS | 24.25% | -6.89% | 15.78% | 14.34% | -29.09% |
| EPS Diluted | 24.55% | 66.09% | 15.79% | 17.07% | 37.45% |
| Normalized Diluted EPS | 24.25% | -6.89% | 15.78% | 14.34% | -29.09% |
| Average Basic Shares Outstanding | 2.86% | 11.33% | 20.55% | 19.87% | 19.84% |
| Average Diluted Shares Outstanding | 2.86% | 11.33% | 20.55% | 19.87% | 19.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |